View in EDS HTML Full Text PDF Full Text

Evaluation of the effects of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR‐Preserved Trial

Saved in:
Bibliographic Details
Title: Evaluation of the effects of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR‐Preserved Trial
Authors: Anker, Stefan D.1 (AUTHOR), Butler, Javed2 (AUTHOR), Filippatos, Gerasimos S.3,4 (AUTHOR), Jamal, Waheed5 (AUTHOR), Salsali, Afshin6 (AUTHOR), Schnee, Janet6 (AUTHOR), Kimura, Karen7 (AUTHOR), Zeller, Cordula8 (AUTHOR), George, Jyothis5 (AUTHOR), Brueckmann, Martina5,9 (AUTHOR), Zannad, Faiez10 (AUTHOR), Packer, Milton11,12 (AUTHOR) milton.packer@baylorhealth.edu, Perrone, Sergio (AUTHOR), Nicholls, Stephen (AUTHOR), Janssens, Stefan (AUTHOR), Bocchi, Edmar (AUTHOR), Giannetti, Nadia (AUTHOR), Verma, Subodh (AUTHOR), Jian, Zhang (AUTHOR), Gomez Mesa, Juan Esteban (AUTHOR)
Source: European Journal of Heart Failure. Oct2019, Vol. 21 Issue 10, p1279-1287. 9p. 1 Diagram, 1 Chart.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:13889842
DOI:10.1002/ejhf.1596